Business
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology -
About this update from Cg Oncology, Inc.
[{"type":"text","content":"- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology’s clinical trial program, including translational data, planned - IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part of American Urological Association (AUA)’s Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s). Designed to showcase the exceptional, groundbreaking studies that are expected to change the day-to-day practice of urology, P2s are reserved for the most impactful studies and will be presented on the Plenary stage. Additionally, CG Oncology will present updates to ongoing clinical trials evaluating cretostimogene across the non-muscle invasive bladder cancer (NMIBC) treatment landscape which are expected to influence urology practice, as well as one interactive poster on translational data. The AUA Annual Meeting, scheduled from April 26-29, 2025, in Las Vegas, Nevada, is the largest gathering of urologists in the world, where leaders in the field share groundbreaking research, new guidelines and the latest advances in urologic medicine. CG Oncology will have a series of key presentations and updates on cretostimogene grenadenorepvec including: P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In SituSession: Saturday Morning Plenary SessionPresenter: Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, ArizonaPresentation Date & Time: Saturday, April 26, 2025, 10:40 AM to 10:50 AM PTLocation: Venetian Ballroom, The Venetian Convention & Expo Center IP02-28: Translational Correlates using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Updated Analysis from the BOND-003 ...